Paradigm Biopharmaceuticals (ASX:PAR) has received a vote of confidence from its CEO and director, Paul Rennie, who has purchased $100,618.95 worth of shares on-market.
The 285,000 shares purchased by entities related to Rennie increased his total number of direct and indirect shares held to 22.1 million.
The next steps for Paradigm will be to focus on completing the Phase 2 Bone Marrow Edema clinical trial and commencing the Ross River clinical trial.